241 related articles for article (PubMed ID: 7734807)
1. Growth hormone treatment of idiopathic short stature: analysis of the database from KIGS, the Kabi Pharmacia International Growth Study.
Ranke MB; Lindberg A
Acta Paediatr Suppl; 1994 Dec; 406():18-23; discussion 24. PubMed ID: 7734807
[TBL] [Abstract][Full Text] [Related]
2. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study.
Ranke MB; Lindberg A; Chatelain P; Wilton P; Cutfield W; Albertsson-Wikland K; Price DA
J Clin Endocrinol Metab; 1999 Apr; 84(4):1174-83. PubMed ID: 10199749
[TBL] [Abstract][Full Text] [Related]
3. Final height in idiopathic growth hormone deficiency: the KIGS experience. KIGS International Board.
Cutfield W; Lindberg A; Albertsson Wikland K; Chatelain P; Ranke MB; Wilton P
Acta Paediatr Suppl; 1999 Feb; 88(428):72-5. PubMed ID: 10102057
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of children with idiopathic short stature in the Kabi Pharmacia International Growth Study, and their response to growth hormone treatment. International Board of the Kabi Pharmacia International Growth Study.
Albertsson-Wikland K
Acta Paediatr Suppl; 1993 Sep; 82 Suppl 391():75-8. PubMed ID: 8219481
[TBL] [Abstract][Full Text] [Related]
5. Growth response in prepubertal children with idiopathic growth hormone deficiency during the first two years of treatment with human growth hormone. Analysis of the Kabi Pharmacia International Growth Study.
Ranke MB; Guilbaud O
Acta Paediatr Scand Suppl; 1991; 379():109-15; discussion 116. PubMed ID: 1815451
[TBL] [Abstract][Full Text] [Related]
6. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.
Ranke MB; Lindberg A; Price DA; Darendeliler F; Albertsson-Wikland K; Wilton P; Reiter EO;
Horm Res; 2007; 68(2):53-62. PubMed ID: 17228181
[TBL] [Abstract][Full Text] [Related]
7. Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS.
Ranke MB; Lindberg A; Albertsson-Wikland K; Wilton P; Price DA; Reiter EO
J Clin Endocrinol Metab; 2005 Apr; 90(4):1966-71. PubMed ID: 15634724
[TBL] [Abstract][Full Text] [Related]
8. Response to growth hormone with respect to pubertal status on increased dose in idiopathic growth hormone deficiency: an analysis of Turkish children in the KIGS database (Pfizer International Growth Study).
Darendeliler F; Berberoğlu M; Ocal G; Adiyaman P; Bundak R; Günöz H; Baş F; Darcan S; Gökşen D; Arslanoğlu I; Yildiz M; Ercan O; Ercan G; Ozerkan E; Can S; Böber E; Adal E; Sarikaya S; Dallar Y; Siklar Z; Bircan I; Bideci A; Yüksel B; Büyükgebiz A
J Pediatr Endocrinol Metab; 2005 Oct; 18(10):949-54. PubMed ID: 16355808
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature.
Hughes IP; Harris M; Choong CS; Ambler G; Cutfield W; Hofman P; Cowell CT; Werther G; Cotterill A; Davies PS;
Clin Endocrinol (Oxf); 2012 Jul; 77(1):62-71. PubMed ID: 21950731
[TBL] [Abstract][Full Text] [Related]
10. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database).
Darendeliler F; Ranke MB; Bakker B; Lindberg A; Cowell CT; Albertsson-Wikland K; Reiter EO; Price DA
Horm Res; 2005; 63(1):40-7. PubMed ID: 15627781
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone treatment in Aarskog syndrome: analysis of the KIGS (Pharmacia International Growth Database) data.
Darendeliler F; Larsson P; Neyzi O; Price AD; Hagenäs L; Sipilä I; Lindgren AC; Otten B; Bakker B;
J Pediatr Endocrinol Metab; 2003; 16(8):1137-42. PubMed ID: 14594174
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone treatment of short children born small for gestational age or with Silver-Russell syndrome: results from KIGS (Kabi International Growth Study), including the first report on final height.
Ranke MB; Lindberg A
Acta Paediatr Suppl; 1996 Oct; 417():18-26. PubMed ID: 9055904
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Dutch Growth Hormone Working Group.
Wit JM; Boersma B; de Muinck Keizer-Schrama SM; Nienhuis HE; Oostdijk W; Otten BJ; Delemarre-Van de Waal HA; Reeser M; Waelkens JJ; Rikken B
Clin Endocrinol (Oxf); 1995 Apr; 42(4):365-72. PubMed ID: 7750190
[TBL] [Abstract][Full Text] [Related]
14. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
Bakker NE; Lindberg A; Heissler J; Wollmann HA; Camacho-Hübner C; Hokken-Koelega AC;
J Clin Endocrinol Metab; 2017 May; 102(5):1702-1711. PubMed ID: 28323917
[TBL] [Abstract][Full Text] [Related]
15. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.
Lanes R; Gunczler P; Esaa S; Weisinger JR
Clin Endocrinol (Oxf); 2002 Dec; 57(6):725-30. PubMed ID: 12460321
[TBL] [Abstract][Full Text] [Related]
16. Growth in pre-pubertal children with myelomeningocele (MMC) on growth hormone (GH): the KIGS experience.
Trollmann R; Bakker B; Lundberg M; Doerr HG
Pediatr Rehabil; 2006; 9(2):144-8. PubMed ID: 16449073
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort.
Maghnie M; Ranke MB; Geffner ME; Vlachopapadopoulou E; Ibáñez L; Carlsson M; Cutfield W; Rooman R; Gomez R; Wajnrajch MP; Linglart A; Stawerska R; Clayton PE; Darendeliler F; Hokken-Koelega ACS; Horikawa R; Tanaka T; Dörr HG; Albertsson-Wikland K; Polak M; Grimberg A
J Clin Endocrinol Metab; 2022 Nov; 107(12):3287-3301. PubMed ID: 36102184
[TBL] [Abstract][Full Text] [Related]
18. Recombinant growth hormone therapy for prepubertal children with idiopathic short stature in Korea: a phase III randomized trial.
Kim J; Suh BK; Ko CW; Lee KH; Shin CH; Hwang JS; Kim HS; Chung WY; Kim CJ; Han HS; Kwon NY; Cho SY; Yoo HW; Jin DK
J Endocrinol Invest; 2018 Apr; 41(4):475-483. PubMed ID: 29103133
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.
Kriström B; Aronson AS; Dahlgren J; Gustafsson J; Halldin M; Ivarsson SA; Nilsson NO; Svensson J; Tuvemo T; Albertsson-Wikland K
J Clin Endocrinol Metab; 2009 Feb; 94(2):483-90. PubMed ID: 19001519
[TBL] [Abstract][Full Text] [Related]
20. Short- and long-term (final height) data in children with normal variant short stature treated with growth hormone.
Schmitt K; Blümel P; Waldhör T; Lassi M; Tulzer G; Frisch H
Eur J Pediatr; 1997 Sep; 156(9):680-3. PubMed ID: 9296529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
